Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Days Payable Outstanding

The Days Payable Outstanding (DPO) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 8, 2026 is 81.06. In the previous year, Days Payable Outstanding (DPO) was 83.97 — a change of -3.46% (lower).

Days Payable Outstanding

81.06

YoY

-3.46%

Last updated:

Days Payable Outstanding (DPO) of Vcanbio Cell & Gene Engineering Corp is 2025 81.06 . Days Payable Outstanding (DPO) of Vcanbio Cell & Gene Engineering Corp was 2024 83.97 . It decreases by -3.46% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
56.01 CNY
Jan 1, 2019
59.10 CNY
Jan 1, 2020
65.90 CNY
Jan 1, 2021
53.66 CNY
Jan 1, 2022
75.21 CNY
Jan 1, 2023
74.70 CNY
Jan 1, 2024
83.97 CNY
Jan 1, 2025
81.06 CNY
The Vcanbio Cell & Gene Engineering Corp Days Payable Outstanding history
YEARDays Payable OutstandingYoY
81.06-3.46%
83.97+12.40%
74.70-0.67%
75.21+40.17%
53.66-18.58%
65.90+11.51%
59.10+5.52%
56.01+15.07%
48.67-25.91%
65.70+27.94%
51.35-40.22%
85.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Days Payable Outstanding (DPO) of Vcanbio Cell & Gene Engineering Corp is 81.06 in 2025.

Days Payable Outstanding (DPO) of Vcanbio Cell & Gene Engineering Corp changed from 83.97 to 81.06, representing a -3.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Vcanbio Cell & Gene Engineering Corp

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Vcanbio Cell & Gene Engineering Corp